| Literature DB >> 33560007 |
Seung Yeon Rhee1, Hyoung Seop Kim.
Abstract
BACKGROUND: Lithium can cause not only acute neurotoxicity but also chronic and persistent neurotoxicity known as syndrome of irreversible lithium-effectuated neurotoxicity (SILENT). The combined use of lithium and antipsychotics increases the possibility of SILENT. Neuroleptic malignant syndrome (NMS) is a reversible, idiosyncratic, and potentially life-threatening reaction, which is usually caused by antipsychotics and other agents, such as mood stabilizers (eg, lithium and metoclopramide). Neuroleptic malignant syndrome is characterized by hyperpyrexia, muscle rigidity, and altered mental status. We describe a case of SILENT combined with NMS in this case report. CASE REPORT: A 46-year-old man who had been treated with lithium for bipolar II disorder since 2008 was prescribed lorazepam, lithium, and aripiprazole at his last outpatient visit. The patient experienced financial difficulties (bankruptcy) and suffered severe emotional stress. Subsequently, he overused lorazepam, lithium, and aripiprazole. Two days after the overdose, he experienced a high fever, confused mental status, and rhabdomyolysis and was diagnosed with NMS. However, even after resolution of NMS-related symptoms, quadriplegia, visual field defects, ataxia, and severe dysarthria persisted. A positron emission tomography-computed tomography brain scan showed decreased 15F-fludeoxyglucose uptake in bilateral primary motor cortices and in the thalamus, midbrain, and cerebellum. Brain magnetic resonance imaging diffusion tensor imaging and diffusion tensor tractography of the subcortical tracts revealed structural disruptions, especially in the corticospinal tract, dentatorubrothalamic tract, and optic radiation, which seemed to be correlated with the clinical symptoms of the patient.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33560007 PMCID: PMC7969158 DOI: 10.1097/WNF.0000000000000439
Source DB: PubMed Journal: Clin Neuropharmacol ISSN: 0362-5664 Impact factor: 1.379
FIGURE 1Brain MRI T2 Axial and T2 FLAIR Sagittal (2019.1.18). There was no remarkable finding.
FIGURE 2PET-CT brain scan (2019.5.15). Decreased FDG uptake in bilateral primary motor cortices (red arrow), thalamus (white arrow), midbrain (red arrowhead), and cerebellum (white arrowhead) was shown.
FIGURE 3Brain MRI T2 FLAIR Axial and T1 Sagittal (2019.6.14). There was no remarkable finding. Compared with a previous study (2019.1.8), no interval change was observed.
FIGURE 4DTT of CST (A, B, C), optic radiation (d), and DRTT (E, F) (June 14, 2019). Subcortical disruptions were observed. (Arrows and arrowheads: suspected disruption of each tracts) (red: left, blue: right).
Hand Function Test
| January 2019 | July 2019 | |
|---|---|---|
| Pinch power (kg) | ||
| Tip pinch | ||
| Rt. | 1.6 | 5.5 |
| Lt. | NT | NT |
| Lateral pinch | ||
| Rt. | 3.8 | 9 |
| Lt. | 1 | 3.5 |
| Palmar pinch | ||
| Rt. | 2.5 | 8.5 |
| Lt. | NT | NT |
| Box and block (/min) | ||
| Rt. | 14 | 13 |
| Lt. | NT | 6 |
| Grip power (kg) | ||
| Rt. | 4 | 26 |
| Lt. | NT | 9 |
NT indicates not testable; Rt., right; Lt., left.
Speech Test (Paradise K-WAB)
| January 2019 | May 2019 | June 2019 | |
|---|---|---|---|
| AQ | 92.4 | 94.5 | 96.2 |
| LQ | — | 92.5 | 94.6 |
| MPT | 2.45 s | 20.83 s | 10.44 s |
| DDK | |||
| AMR | 8 times/5 s | 13 times/5 s | |
| AMR | 6 times/5 s | 13.7times/5 s | |
| AMR | 5 times/5 s | 12 times/5 s | |
| SMR | 2 times/5 s | 4 times/5 s | |
K-WAB indicates Korean version—the Western Aphasia Battery; AQ, aphasia quotient; LQ, language quotient; MPT, maximum phonation time; DDK, diadochokinetic rate; AMR, alterate motion rate; SMR, sequencing motion rate.
International Cooperative Ataxia Rating Scale (ICARS)
| June 2019 | July 2019 | |
|---|---|---|
| Posture and gait disturbances | ||
| Walking capacities | 8 | 8 |
| Gait speed | 4 | 4 |
| Standing capacities, eyes open | 5 | 5 |
| Spread of feet in natural position/s support, eyes open | 4 | 2 |
| Body sway with feet together, eyes open | 4 | 3 |
| Body sway with feet together, eyes closed | 4 | 4 |
| Quality of sitting position | 1 | 0 |
| Kinetic functions | ||
| Knee-tibia test (decomposition of movement and intention tremor) | 3/4 | 3/3 |
| Action tremor in the heel to knee test | 3/3 | 2/2 |
| Finger to nose test: decomposition and dysmetria | 2/3 | 2/3 |
| Finger to nose test: intention tremor of finger | 2/3 | 2/2 |
| Finger-finger test (action tremor and/or instability) | 2/3 | 2/2 |
| Pronation supination alternating movements | 2/3 | 1/2 |
| Drawing of Archimedes' spiral on a predrawn pattern | 2 | 1 |
| Speech disorders | ||
| Dysarthria: fluency of speech | 3 | 3 |
| Dysarthria: clarity of speech | 2 | 2 |
| Oculomotor disorders | ||
| Gaze-evoked nystagmus | 1 | 1 |
| Abnormalities of ocular pursuit | 1 | 1 |
| Dysmetria of saccade | 0 | 0 |
| Total | 72/100 | 60/100 |